NCT04447833View on ClinicalTrials.gov

Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

January 30, 2021

Study Completion Date

March 30, 2026

Conditions
ARDS, HumanCOVID
Interventions
DRUG

Mesenchymal Stromal Stem Cells - KI-MSC-PL-205

Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).

Trial Locations (1)

75185

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Uppsala University Hospital

OTHER

lead

Uppsala University

OTHER

NCT04447833 - Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter